PT653942E - Regeneracao e reparacao de nervos induzidos por morfogenios - Google Patents

Regeneracao e reparacao de nervos induzidos por morfogenios

Info

Publication number
PT653942E
PT653942E PT93918560T PT93918560T PT653942E PT 653942 E PT653942 E PT 653942E PT 93918560 T PT93918560 T PT 93918560T PT 93918560 T PT93918560 T PT 93918560T PT 653942 E PT653942 E PT 653942E
Authority
PT
Portugal
Prior art keywords
neurons
mammal
stimulating
morphogenes
reparation
Prior art date
Application number
PT93918560T
Other languages
English (en)
Inventor
Thangavel Kuberasampath
Charles M Cohen
David C Rueger
Hermann Oppermann
Roy H L Pang
Engin Ozkaynak
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27363454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT653942(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Curis Inc filed Critical Curis Inc
Publication of PT653942E publication Critical patent/PT653942E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/32—Materials or treatment for tissue regeneration for nerve reconstruction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
PT93918560T 1992-07-31 1993-07-29 Regeneracao e reparacao de nervos induzidos por morfogenios PT653942E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92281392A 1992-07-31 1992-07-31
US2933593A 1993-03-04 1993-03-04
US4051093A 1993-03-31 1993-03-31

Publications (1)

Publication Number Publication Date
PT653942E true PT653942E (pt) 2003-11-28

Family

ID=27363454

Family Applications (1)

Application Number Title Priority Date Filing Date
PT93918560T PT653942E (pt) 1992-07-31 1993-07-29 Regeneracao e reparacao de nervos induzidos por morfogenios

Country Status (10)

Country Link
EP (1) EP0653942B2 (pt)
JP (3) JP4344012B2 (pt)
AT (1) ATE242639T1 (pt)
AU (1) AU681594B2 (pt)
CA (1) CA2141554C (pt)
DE (1) DE69333040T3 (pt)
DK (1) DK0653942T3 (pt)
ES (1) ES2201059T5 (pt)
PT (1) PT653942E (pt)
WO (1) WO1994003200A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506729B1 (en) 1991-03-11 2003-01-14 Curis, Inc. Methods and compositions for the treatment and prevention of Parkinson's disease
US6723698B2 (en) 1991-03-11 2004-04-20 Curis, Inc. Methods and compositions for the treatment of motor neuron injury and neuropathy
US6495513B1 (en) 1991-03-11 2002-12-17 Curis, Inc. Morphogen-enhanced survival and repair of neural cells
DE69333040T3 (de) * 1992-07-31 2007-10-11 Curis, Inc., Cambridge Morphogen induzierte nerven wiederherstellung und wiedergutmachung.
AU5129293A (en) * 1992-09-15 1994-04-12 Creative Biomolecules, Inc. 60a protein-induced morphogenesis
DE69434875T2 (de) 1993-05-12 2007-09-06 Genetics Institute, LLC, Cambridge BMP-11 Zusammenstellungen
EP0716610B1 (en) * 1993-08-26 2006-05-17 Genetics Institute, LLC Human bone morphogenetic proteins for use in neural regeneration
US5669407A (en) * 1994-03-24 1997-09-23 Masco Corporation Of Indiana Compression cartridge for a faucet valve assembly
WO1996030038A1 (en) * 1995-03-29 1996-10-03 The Rockefeller University Peptide growth factor having epidermal inducing activity
JP4847634B2 (ja) 1996-03-22 2011-12-28 ストライカー・コーポレーション 中枢神経系の虚血または外傷の機能的回復を増大させる方法
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5928940A (en) * 1996-09-24 1999-07-27 Creative Biomolecules, Inc. Morphogen-responsive signal transducer and methods of use thereof
AU4726597A (en) * 1996-10-31 1998-05-22 Nippon Shinyaku Co. Ltd. Cranial nerve cell protectives
WO1998020889A1 (en) * 1996-11-15 1998-05-22 Creative Biomolecules Inc Morphogen peptide-induced regeneration of sense perceptory tissues
ATE278414T1 (de) * 1997-05-05 2004-10-15 Curis Inc Therapien zur behandlung von akutem nierenversagen
EP0985149A1 (en) * 1997-05-30 2000-03-15 Creative Biomolecules, Inc. Methods for evaluating tissue morphogenesis and activity
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US7147839B2 (en) * 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
CA2349038C (en) † 1998-11-13 2011-08-02 Curis, Inc. Methods of alleviating cancer symptoms
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
JP4654029B2 (ja) 2002-06-17 2011-03-16 トラソス インコーポレイテッド 単一ドメインｔｄｆ関連化合物およびその類似体
AU2005265098B2 (en) 2004-06-17 2012-02-23 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
CN101031645B (zh) * 2004-06-23 2011-06-08 组织基因股份有限公司 神经再生
PT2497780E (pt) 2005-09-20 2015-08-20 Thrasos Innovation Inc Compostos relacionados com tdf e seus análogos
CA2718592A1 (en) 2008-02-13 2009-08-20 Keith Hruska Method of treating vascular sclerosis
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
MA47163A (fr) * 2016-12-16 2019-11-06 Biogen Ma Inc Facteur 11 de différenciation de croissance activé protéolytiquement stabilisé

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE01201555T1 (de) * 1988-04-08 2004-07-08 Stryker Corp., Kalamazoo Biosynthetische osteogene Proteine und solche enthaltende osteogene Einrichtungen
ES2113857T3 (es) * 1989-03-28 1998-05-16 Genetics Inst Composiciones osteoinductoras.
ES2137931T3 (es) * 1990-06-15 2000-01-01 Carnegie Inst Of Washington Proteinas gdf-1 y uog-1.
ATE203166T1 (de) * 1991-03-11 2001-08-15 Curis Inc Protein-induzierende morphogenese
JP3504263B2 (ja) * 1991-11-04 2004-03-08 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー 組み換え型骨形態形成蛋白ヘテロダイマー、組成物および使用法
DE69333040T3 (de) * 1992-07-31 2007-10-11 Curis, Inc., Cambridge Morphogen induzierte nerven wiederherstellung und wiedergutmachung.

Also Published As

Publication number Publication date
DE69333040T2 (de) 2004-05-06
EP0653942B2 (en) 2007-03-07
WO1994003200A1 (en) 1994-02-17
ES2201059T5 (es) 2007-11-01
EP0653942B1 (en) 2003-06-11
ATE242639T1 (de) 2003-06-15
JP4344012B2 (ja) 2009-10-14
AU4797193A (en) 1994-03-03
DE69333040D1 (de) 2003-07-17
JP2005287512A (ja) 2005-10-20
CA2141554C (en) 2003-02-11
ES2201059T3 (es) 2004-03-16
AU681594B2 (en) 1997-09-04
DE69333040T3 (de) 2007-10-11
DK0653942T3 (da) 2003-10-20
JPH07509721A (ja) 1995-10-26
JP2009227679A (ja) 2009-10-08
CA2141554A1 (en) 1994-02-17
EP0653942A1 (en) 1995-05-24

Similar Documents

Publication Publication Date Title
PT653942E (pt) Regeneracao e reparacao de nervos induzidos por morfogenios
DE69232008D1 (de) Verwendung von insulinähnlichen Wachstumsfaktoren und Analogen zur BEHANDLUNG VON ERKRANKUNGEN DER SEHNERVEN
Gordon et al. The resilience of the size principle in the organization of motor unit properties in normal and reinnervated adult skeletal muscles
ATE341363T1 (de) Verfahren und vorrichtung zum dauerhaften verändern einer neuralen funktion eines patienten
EA200200847A1 (ru) Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов
US20020035358A1 (en) Pulsed electromagnetic field therapy for treatment of corneal disorders and injuries
ATE323482T1 (de) Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten
ATE381935T1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
DE69222362D1 (de) Implantierbare Vorrichtung zur Herzrhythmuskorrektur, Herzreizung und Defibrillation mit unterschiedlichen Stimulationsfrequenzen zum unterstützen von Bradykardien
EP1531899A4 (en) SELECTIVE NERVOUS FIBER STIMULATION FOR THE TREATMENT OF HEART DISEASES
ATE434975T1 (de) Vorrichtung und verfahren zur repositionierung von patienten
ES2143611T3 (es) Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteinasas.
ATE280758T1 (de) Mittel zum schutz von nervenzellen
DE69936381D1 (de) Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie
FR2760369B1 (fr) Stimulateur cardiaque multisites pour le traitement des insuffisances cardiaques par stimulation
ES2114073T3 (es) Regeneracion del higado inducida por morfogenes.
ATE415977T1 (de) Methode zum screening von anti-amyloidogenen eigenschaften und methode zur behandlung neurodegenerativer krankheiten
Lund et al. Cortical reorganization and deafferentation in adult macaques
BR9906926A (pt) Composições e métodos para tratamento de células tendo dna de minuto duplo
EP0214017A3 (en) Use of n,n,-dimethylbiguanid p-chorophenoxyacetate in the treatment of neuropathies and nerval degeneration
DE59907195D1 (de) Verfahren zur behandlung von erkrankungen oder störungen des innenohrs
PT1131073E (pt) Uso de derivados de estaurosporina para o tratamento de doencas oculares neovasculares
Lee et al. Nerve growth factor expression in stroke induced rats after shock wave
PT1255734E (pt) Derivados de isatina com actividade neurotrofica
BR9710893A (pt) Uso de tiagabina ou de um sal farmaceuticamente aceit vel da mesma e processos de tratamento de distÚrbios psicÄticos e de distÚrbios de mania em seres humanos ou em animais